SCHEMBL6103013

SCHEMBL6103013

CC1CCCCN1c1ccc(Br)cc1C=CC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 3/20 0.37
TP53 P04637 3/20 0.37
KMT2A Q03164 2/20 0.37
GAA P10253 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HPGD P15428 2/20 0.36
LMNA P02545 1/20 0.36
PMP22 Q01453 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
POLB P06746 1/20 0.36
GPBAR1 Q8TDU6 1/20 0.36
NR1I2 O75469 2/20 0.35
SMARCA2 P51531 2/20 0.35
SMARCA4 P51532 2/20 0.35
NR1H3 Q13133 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6103009 1.00 GFER (0.46) GFERSMN1; SMN2MAPTTP53KMT2A
SCHEMBL6104164 0.96 GFER (0.42) GFERSMN1; SMN2MAPTKMT2AMEN1
SCHEMBL6104169 0.96 GFER (0.42) GFERSMN1; SMN2MAPTKMT2AMEN1
SCHEMBL411118 0.82 GFER (0.46) GFERSMN1; SMN2MAPTTP53KMT2A
SCHEMBL6103241 0.82 SMN1; SMN2 (0.41) GFERSMN1; SMN2MAPTKMT2AGAA
SCHEMBL6103247 0.82 SMN1; SMN2 (0.41) GFERSMN1; SMN2MAPTKMT2AGAA
SCHEMBL31393389 0.81 GFER (0.43) GFERMAPTTP53KMT2AGAA
SCHEMBL6104095 0.81 GAA (0.41) GFERSMN1; SMN2MAPTKMT2AGAA
SCHEMBL6105724 0.81 GAA (0.41) GFERSMN1; SMN2MAPTKMT2AGAA
SCHEMBL6103607 0.81 GAA (0.41) GFERSMN1; SMN2MAPTKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160864-A1 Acrylamide derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-20 US disclosed
EP-1593673-A1 ACRYLAMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160864-A1 Acrylamide derivative, process for producing the same, and use CCR5, MSR1, CCR2 GFER 156/4885SMN1; SMN2 2871/4885MAPT 4646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.